Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.
Jason M. Broderick, OncLive
Advertisement
Articles by Jason M. Broderick, OncLive
Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.
Advertisement
Latest Updated Articles
Lung Cancer Combination Therapy Shows PromiseFebruary 16th 2016
Combination Therapy Shows Promise in Lung CancerFebruary 16th 2016
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5